| Drug Type Fc fusion protein | 
| Synonyms- | 
| Target | 
| Action antagonists | 
| Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR4 antagonists(Fibroblast growth factor receptor 4 antagonists), GLP-1R antagonists(Glucagon-like peptide 1 receptor antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Metabolic dysfunction-associated steatotic liver disease | Preclinical | United States  | 10 May 2024 | 






